The Liver Meeting 2021-Controversies in the Screening and Prevention of Clinically Significant Portal Hypertension

Controversies in the Screening and Prevention of Clinically Significant Portal Hypertension

Video Transcription

Video Summary

A meta-analysis by Dr. Villanueva and colleagues examined carvetilol's use in preventing decompensation in cirrhosis patients, showing reduced risks of decompensation, variceal bleeding, and mortality. Non-invasive methods can identify high-risk patients. Current portal hypertension treatments target reducing intrahepatic resistance, including non-selective beta blockers, statins, belapectin, metformin, taurine, and FXR agonists. Precision medicine may be key in tailoring treatments based on disease stage and pathophysiological factors, utilizing biomarkers and omics data. Challenges in assessing treatment response are highlighted, with a focus on seeking non-invasive monitoring methods, especially concerning microcirculation effects. Future advancements may lead to personalized therapies and enhanced monitoring techniques, ultimately improving patient outcomes. Active clinical trials remain crucial for evaluating new interventions and optimizing the management of portal hypertension.

Keywords

meta-analysis

Dr. Villanueva

carvetilol

cirrhosis

decompensation

variceal bleeding

mortality

portal hypertension

non-selective beta blockers

precision medicine

biomarkers

omics data

microcirculation effects